Compugen

Drug Discovery Using Computational Modeling

Health Tech & Life Sciences
Public on NASDAQ on Aug, 2000
Public on TASE on Jan, 2002
Public Holon, Israel Founded 1993
Last updated 2026-06-18
Total raised
$141.9M
Last: PIPE 2021-11
Stage
Public
Founded
1993
Headcount
113
HQ
Holon, Israel
Sector
Health Tech & Life Sciences

About

Compugen is a clinical-stage drug-discovery and development company with a broadly applicable predictive-discovery infrastructure that is advancing a therapeutic pipeline consisting mainly of early-stage immuno-oncology programs aimed at harnessing the immune system to eradicate cancer. The company's pipeline is based on novel Compugen-discovered drug targets, primarily immune checkpoint candidates that are predicted to provide cancer immunotherapies addressing unmet cancer types and patient populations, both as monotherapies and in combination. In 2010, Compugen chose to specialize in oncology and immunology, with a focus on immuno-oncology. Compugen's first application of its predictive discovery infrastructure was in the field of immune checkpoints, with the goal of developing novel, effective cancer immunotherapies. The company has also expanded its discovery capabilities to include myeloid target candidates within the tumor microenvironment. Today, Compugen's pipeline includes multiple opportunities for therapeutics addressing areas of unmet medical need in the field of oncology.

Funding history · 4 rounds · $141.9M total

2007-07
PIPE $4.9M
2013-01
2018-10
2021-11

Q&A

What is Compugen's primary focus?
Compugen is a clinical-stage drug-discovery and development company specializing in immuno-oncology programs, aiming to use the immune system to fight cancer.
When was Compugen founded?
Compugen was founded in February 1993.
How many employees does Compugen have?
Compugen has 51-200 employees.
What is Compugen's current market capitalization?
Compugen's market capitalization is $143,169,739 USD.
When did Compugen last raise a PIPE round and who participated?
In November 2021, Compugen raised a $20,000,000 PIPE round with participation from Bristol-Myers Squibb Company.
What is the total amount of funding Compugen has raised to date?
Compugen has raised a total of $141,920,000 USD.
When did Compugen conduct its most recent public offering?
In March 2020, Compugen conducted a public offering on NASDAQ, raising $75,000,000 USD.
Where is Compugen's headquarters located?
Compugen's headquarters is located in Holon, Center District, Israel.
Who is the President & CEO of Compugen?
Anat Cohen-Dayag Ph.D. is the President & CEO of Compugen.

Team · 5

SVP & Senior Advisory, Computational Discovery
LinkedIn ↗
Senior Vice President, Technology Innovation
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug Delivery
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B

Highlights

1 Patents

Tags

immunologyoncologybiotechnologybioinformaticsantibodiesdrug-discoveryproteinspharmaceuticalsimmunotherapycancer-therapyautoimmune-diseasespatientspharma-companiescancer
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)